INTRODUCTION {#SEC1}
============

SIRT7 belongs to NAD^+^-dependent sirtuin family, which predominantly localizes to nucleolus and widely expressed in various organs and tissues ([@B1],[@B2]). SIRT7 interacts with mTOR and GTF3C1, thus regulating protein synthesis ([@B3]), and cooperates with Myc to suppress ribosome biogenesis ([@B4]). SIRT7 regulates DNA damage response and DNA repair via facilitating recruitment of 53BP1 and inhibition of ATM deacetylation ([@B5],[@B6]). 5-Fluorouracil (5-FU)-induced *SIRT7* reduction promotes radiosensitivity in colorectal cancer ([@B7]). *Sirt7^--^*^/^*^--^* mice suffer from genomic instability, cardiomyopathy, hepatic steatosis as well as early death ([@B8],[@B9]). Bone marrow and liver carry high level of SIRT7, which regulates hematopoietic stem cell aging and hepatic lipid metabolism ([@B4],[@B10],[@B11]). Upon energetic stress, SIRT7 is released from nucleolus and degraded by REGγ ([@B12]). SIRT7 is progressively downregulated and thus activates TGF-β signaling during breast cancer metastasis ([@B13]). MicroRNAs, such as miR-125b, miR-125a-5p, hsa-miR-125b, miR-93 and miR-3666, negatively regulate *SIRT7* expression in various cancers and adiposity ([@B14]). Albeit advances affirming pivotal function and post-transcriptional regulation of SIRT7, how SIRT7 is transcriptionally regulated is still elusive.

TGF-β signaling is highly conserved in multicellular organisms, involved in multiple cellular processes, such as cell growth, stemness, migration and invasion, epithelial--mesenchymal transition (EMT), extracellular matrix (ECM) remodeling and immune regulation ([@B18]). The canonical TGF-β signaling is initially transduced through the formation of a heterotetrametric receptor complex composed of TGF-β type I (TβRI) and type `II` (TβR`II`) receptors. Activated TβRI phosphorylates SMAD2 and SMAD3 (R-SMADs) at C-terminal serine residues, allowing them to assemble into homomeric complex and then to form heterotrimeric complex with SMAD4 (Co-SMAD). These complexes translocate to the nucleus, wherein regulating the transcription of dozens of genes ([@B19],[@B20]). In certain case, SMAD3 recruits histone deacetylases HDAC4/5 to achieve transcriptional repression of *Runx2* via local chromatin condensation ([@B21]). So far, however, the evidences that HDACs cooperate with SMADs to modify histone acetylation are still few. Their target genes and physiological roles need to be further explored.

HDAC8 is a class I HDAC that deacetylates histone H3 and H4 at nonspecific lysines ([@B22],[@B23]). HDAC8 coordinates with DEC1 to suppress the transcription of TAp73 and DeltaNp73; HDAC8/YY1 signals suppress mutant *p53* transcription in triple negative breast cancer (TNBC) cells ([@B24],[@B25]). So far, however identified HDAC8 target genes are few, which restrains its mechanism clarification. Here, we reveal a feedback loop that regulates TGF-β signaling--HDAC8 forms complex with SMAD3/4 heterotrimers and represses *SIRT7* transcription via local chromatin remodeling; reduction of SIRT7 further activates TGF-β signaling. The data highlight that manipulating level of SIRT7 or HDAC8 has great therapeutic potential for TGF-β signaling-related diseases.

MATERIALS AND METHODS {#SEC2}
=====================

Cell lines and chemicals {#SEC2-1}
------------------------

The breast cancer cell lines 4T1, MDA-MB-231, BT549 and HEK 293 human kidney cells were obtained from the American Type Culture Collection (ATCC^®^). 4T1, MDA-MB-231 and HEK 293 cells were cultured in high glucose DMEM (Gibco^®^) supplemented with 10% FBS (Gibco^®^). BT549 cells were cultured in RPMI-1640 (Gibco^®^) supplemented with 10% FBS. All cells were maintained at 37°C in a humidified 5% CO~2~ atmosphere. The ALK5 inhibitor A8301, HDAC8 inhibitor PCI-34051 and paclitaxel were obtained from MedChemExpress (MCE^®^). Other HDAC inhibitors mentioned in manuscript were from Selleck.

Cell transfection {#SEC2-2}
-----------------

Cells were transfected with plasmids or siRNAs using either Polyethyleneimine (PEI) or Lipofectamine^®^3000 (Thermo Fisher), following the manufacturer\'s instructions. Oligo siRNAs or shRNAs were obtained from GenePharma Company (Shanghai). The siRNA sequences are listed in [Supplementary Table S2](#sup1){ref-type="supplementary-material"}.

Lentivirus package and stable cell line selection {#SEC2-3}
-------------------------------------------------

Lentiviral constructs with shRNA, pSPAX2 and pMD2G (1:1:0.5) were co-transfected into HEK293 cells using Lipofectamine^®^3000. After 48 h, the supernatant was collected and filtered through a 0.22 μm membrane (Millipore). The virus titer was measured before infection. 4T1 or MDA-MB-231 cells were infected with shRNA lentivirus and selected with puromycin (Sigma) to obtain stable *Sirt7* knockdown. The oligo shRNA sequences used are listed in [Supplementary Table S2](#sup1){ref-type="supplementary-material"}.

RNA isolation, qRT-PCR and chromatin immunoprecipitation assays (ChIP) {#SEC2-4}
----------------------------------------------------------------------

Cells were lysed in Trizol reagent (RNAiso Plus, Takara) and the total RNA was isolated by standard protocol before transcribing into cDNA using 5 × Primescript^®^ RT Master Mix (Takara), according to the manufacturer\'s instructions. qRT-PCR analysis of gene expression was performed using 2 × SYBR^®^ Green Mix (Takara) on a Bio-Rad detection system. Fast ChIP assays were performed according to previously reported protocols ([@B26]). All primer sequences and ChIP antibodies are listed in [Supplementary Tables S2 and S3](#sup1){ref-type="supplementary-material"}.

Luciferase reporter assay {#SEC2-5}
-------------------------

The SIRT7 promoter sequence predicated at --1930/+54 (S7Pro) was cloned into a pGL4.17 vector (Promega). To monitor promoter activity, the luciferase plasmid and the Renilla luciferase (pRL-CMV) internal control plasmid were co-transfected into breast cancer cells. The transcriptional activity was determined by Dual-Luciferase Reporter Assay System (Promega), performed according to the manufacturer\'s instructions. The SMAD3/SMAD4 binding sites on the SIRT7 promoter were identified using the rVista 2.0 online tool (<https://rvista.dcode.org/>). To mutate the SMAD3/4 binding site on the SIRT7 promoter, site direction mutagenesis was performed by KOD-Plus-Neo (TOYOBO).

Transwell migration assay {#SEC2-6}
-------------------------

For Transwell migration, 5 × 10^4^ cells suspended in 200 μl FBS-free medium were placed in the upper chamber (8 μm pore size, Corning). The insert was incubated in a 24-well-plate supplemented with 500 μl 10% FBS medium as a chemoattractant. The top membrane was swiped with cotton swabs to remove the non-migrated cells, and the migrated cells were stained with crystal violet before the cell number was counted to evaluate the migration ability.

Protein extraction and western blotting {#SEC2-7}
---------------------------------------

Total cell lysate was prepared following RIPA buffer extraction (Thermo Fisher). Protein extracts were resolved in 5× Laemmli sample buffer (100 mM Tris--HCl \[pH6.8\], 4% SDS, 20% glycerol and 1 mM DTT), separated by SDS-PAGE, transferred to a PVDF membrane (Millipore), blocked with 5% non-fat milk and probed with the respective primary antibodies. Immunoblotting images were collected on a Bio-Rad system after incubation with HRP-conjugated secondary antibodies. The antibodies listed in [Supplementary Table S3](#sup1){ref-type="supplementary-material"}.

Immunoprecipitation {#SEC2-8}
-------------------

The indicated cells were first lysed in IP lysis buffer \[200 mM NaCl, 20 mM Tris--HCl (pH 7.9), 5 mM MgCl~2~, 10% glycerol, 0.2 mM EDTA and 0.1% NP-40\] supplemented with protease inhibitors (Roche Complete). After sonication and centrifugation, the cleared cell supernatant was collected and incubated with the respective antibodies for 4 h or overnight at 4°C. The immunoprecipitates were washed with IP lysis buffer and eluted in Laemmli sample buffer for immunoblotting.

*In vivo* xenograft model of breast cancer {#SEC2-9}
------------------------------------------

Pathogen-free female BALB/c mice were purchased from the Shanghai Laboratory Animal Center, CAS (Shanghai). Then, 4T1 cells (5 × 10^5^) were injected into the fourth mammary fat pad of virgin BALB/c mice. After 7 days of inoculation, tumor-bearing mice were randomized for treatment with saline, PCI-34051 (10 mg/kg, i.p.) or paclitaxel (10 mg/kg, i.p.) as indicated. The tumor diameters were measured and the tumor volume (mm^3^) was calculated by the formula: volume = 0.5 × length × width^2^. The lung metastatic nodules were counted after H&E staining of the whole lung. Experimental animals were housed and handled in accordance with protocols approved by the Committee on the Use of Live Animals in Teaching and Research of Shenzhen University.

Statistical analyses {#SEC2-10}
--------------------

All statistical analyses were performed using GraphPad^®^ Prism 5 or Microsoft excel. The data obtained by at least three independent experiments are represented as the means ± s.e.m. Normally distributed data were analyzed by Student\'s *t*-test. Non-normally distributed data were analyzed by non-parametric Mann--Whitney *U*-tests. A *P* \< 0.05 was considered statistically significant.

RESULTS {#SEC3}
=======

TGF-β signaling suppresses *SIRT7* transcription {#SEC3-1}
------------------------------------------------

SIRT7 antagonizes TGF-β signaling via promoting SMAD4 degradation ([@B13]). Based on the intrinsic nature of TGF-β regulatory feedback loop ([@B27]), we examined whether TGF-β signaling in turn represses *SIRT7* expression. We treated MDA-MB-231 cells with TGF-β1 and found that mRNA and protein levels of SIRT7 were both inhibited in a dose-dependent manner (Figure [1A](#F1){ref-type="fig"}, B). This finding was confirmed in two other cell lines ([Supplementary Figure S1A--C](#sup1){ref-type="supplementary-material"}). Of note, phosphorylated SMAD3 and upregulated *PAI1* indicated activated TGF-β signaling ([@B28]). We next exposed the cells to TGFβRI inhibitor A83--01. As shown, blocking TGF-β signaling resulted in significant *SIRT7* upregulation (Figure [1C](#F1){ref-type="fig"}, [D](#F1){ref-type="fig"}). Similarly, A83-01 treatment abolished the TGF-β1-induced downregulation of *SIRT7* in three other cell lines ([Supplementary Figure S1D](#sup1){ref-type="supplementary-material"}). To further confirm that TGF-β1 represses *SIRT7* transcription, we cloned *SIRT7* promoter (proS7) into a PGL-4.17 luciferase reporter system ([Supplementary Figure S1E](#sup1){ref-type="supplementary-material"}). The luciferase activity was significantly inhibited by TGF-β1 (Figure [1E](#F1){ref-type="fig"}), suggestive of transcriptional repression of *SIRT7*.

![TGF-β suppresses *SIRT7* transcription. (**A**, **B**) qRT-PCR (A) and Immunoblotting (B) analysis of SIRT7 levels in MDA-MB-231 cells following TGF-β1 treatment. *PAI1* upregulation indicates TGF-β signaling activation. Data are shown as means ± s.e.m. *n* = 3, \*\*\**P* \< 0.0001; Student\'s *t*-test. (**C**, **D**) MDA-MB-231 cells were incubated with the TβRI inhibitor A83-01 (1, 5 μM). qRT-PCR (C) and Immunoblotting (D) analysis of SIRT7 levels in MDA-MB-231 cells. The data represent the means ± s.e.m. n = 3, \**P* \< 0.05; Student\'s *t*-test. (**E**) Luciferase reporter assay of *SIRT7* promoter activity in MDA-MB-231 cells treated or untreated with TGF-β1 (5 ng/ml) (right). Pgl-null, PGL.417 empty vector with minimal promoter activity; proS7, PGL.417 cloned with the promoter of SIRT7. Immunoblot analysis of p-SMAD3 upon TGF-β1 treatment (left). The data represent the means ± s.e.m. *n* = 3, \**P* \< 0.05 and \*\*\**P* \< 0.0001; Student\'s *t*-test.](gkaa039fig1){#F1}

The effect of TGFβ signaling highly relies on tissue or cellular context ([@B29]). We thus explored whether TGF-β-mediated suppression of *SIRT7* expression is a general effect. As shown, *SIRT7* expression was downregulated upon activation of TGF-β signaling in various tissue-derived cells, including human skin fibroblast F2S cells, human skin keratinocyte HaCat cells and lung cancer A549 cells ([Supplementary Figure S2A](#sup1){ref-type="supplementary-material"}). Of note, colorectal cancer Caco2 cells were insensitive to TGFβ signaling and failed to repress *SIRT7* expression even at high dosage, indicating that the full activation of TGFβ is requisite for *SIRT7* suppression. Further, based on public data (<http://rna.sysu.edu.cn/chipbase/>) ([@B30]), *SIRT7* expression was negatively correlated to *TGFBR1*, *TGFBR2* or *SMAD3* in multiple tissues and cancers ([Supplementary Tables S4--S9](#sup1){ref-type="supplementary-material"}). Together, these data implicate that TGF-β signaling suppresses *SIRT7* expression.

SMAD3/4 underlines TGF-β-induced *SIRT7* suppression {#SEC3-2}
----------------------------------------------------

SMAD2/3 are the major TGF-β signaling modulators ([@B28]). We knocked down *SMAD2* or *SMAD3* via siRNA and monitored *SIRT7* expression induced by TGF-β1. *SMAD2* and *SMAD3* knockdown (KD) attenuated *PAI1* transcription ([Supplementary Figure S2B](#sup1){ref-type="supplementary-material"}). Interestingly, while *SMAD3* KD blocked TGF-β1-induced *SIRT7* repression, *SMAD2* KD had little such effect (Figure [2A](#F2){ref-type="fig"}, B). Consistently, p-SMAD3 levels were reversely correlated with SIRT7 expression in series of breast cancer cell lines ([Supplementary Figure S2C](#sup1){ref-type="supplementary-material"}). As SMAD3 and SMAD4 heterotrimerize to regulate transcription ([@B20]), we asked whether SMAD4 is required for SMAD3-mediated *SIRT7* transcriptional suppression. We knocked down *SMAD4* in MDA-MB-231 cells and confirmed TGF-β1 inhibition by *PAI1* reduction ([Supplementary Figure S2D](#sup1){ref-type="supplementary-material"}, E). As shown, *SMAD4* KD significantly attenuated TGF-β1-induced *SIRT7* downregulation (Figure [2C](#F2){ref-type="fig"}, [D](#F2){ref-type="fig"}). These results suggest that TGF-β signaling suppresses *SIRT7* transcription via SMAD3/4.

![SMAD3/SMAD4 mediates TGF-β-induced *SIRT7* suppression. (**A**) qRT-PCR analysis of *SIRT7* mRNA levels following TGF-β1 (5 ng/ml) treatment and *SMAD2* and *SMAD3* knockdown. Immunoblots showing SMAD2 and SMAD3 levels in MDA-MB-231 cells treated with *SMAD2*, *SMAD3* siRNAs or scrambled siRNA. L, low exposure; H, high exposure. n.s., non-significant. The data represent the means ± s.e.m. *n* = 3, \*\*\**P* \< 0.001; Student\'s *t*-test. (**B**) Immunoblotting analysis of SIRT7 levels in cells treated with TGF-β1 (5 ng/ml) or *SMAD3* siRNA. Increased p-SMAD2 levels indicate TGF-β activation. (**C**, **D**) Immunoblotting (C) and qRT-PCR (D) analysis of SIRT7 levels treated with TGF-β1 (5 ng/ml) and/or *SMAD4* siRNA. The data represent the means ± s.e.m. *n* = 3, \**P* \< 0.05; Student\'s *t*-test. (**E**) Predicated SMAD3/SMAD4 binding sites (SBEs) on the *SIRT7* promoter by the online tool rVISTA 2.0 ([@B31]). The green color highlights the conserved SBE sequence (upper). (**F**) ChIP PCR using a p-SMAD3 antibody in breast cancer cells. *SLUG* serves as a positive control (middle); Fold change of p-SMAD3 enrichment on the *SIRT7* promoter by ChIP-qPCR (below). The data represent the means ± s.e.m. *n* = 3, \**P* \< 0.05; Student\'s *t*-test. (**G**) Fold change of p-SMAD3 enrichment on the *SIRT7* promoter region following *SMAD4* siRNA or TGF-β1 (5 ng/ml) treatment in breast cancer cells, determined by ChIP-qPCR (upper). Immunoblotting (below) of SMAD4 knockdown and TGF-β1 signaling activation. The data represent the means ± s.e.m. *n* = 3, \**P* \< 0.05; Student\'s *t*-test. (H) Luciferase reporter assay (upper) of *SIRT7* promoter activity with/without TGF-β1 (5 ng/ml) treatment. Immunoblotting (below) of endogenous SIRT7 and p-SMAD3 levels under the indicated treatments. n.s, non-significant. The data represent the means ± s.e.m. *n* = 3, \**P* \< 0.05, \*\*\**P* \< 0.001; Student\'s *t*-test.](gkaa039fig2){#F2}

The SMAD3/4 complex recognizes conserved GTCT motif on target gene promoter, known as SMAD binding element (SBE) ([@B19]). We searched for putative SBE motifs on *SIRT7* promoter region using an rVista 2.0 online tool ([@B31]). A highly conserved SBE (--959 to --948 bp) was predicted (Figure [2E](#F2){ref-type="fig"}). To gain experimental evidence, anti p-SMAD3 chromatin immunoprecipitation (ChIP) was conducted. Indeed, p-SMAD3 was significantly enriched on *SIRT7* promoter, which was enhanced by TGF-β1 (Figure [2F](#F2){ref-type="fig"}). *SLUG*, a known transcription target of SMAD3/4 complex, served as a positive control ([@B28]). Further, *SMAD4* KD significantly attenuated TGF-β1-induced SMAD3 enrichment on *SIRT7* promoter (Figure [2G](#F2){ref-type="fig"}). To test the binding specificity, we mutated the core binding motif TGTCTGG (WT) to T[A]{.ul}T[A]{.ul}T[A]{.ul}G (Mutant) ([@B19]) and performed dual-luciferase reporter assay. As shown, the Mutant promoter exhibited much higher luciferase activity compared to WT. TGF-β1 treatment inhibited WT promoter activity but hardly affected the Mutant (Figure [2H](#F2){ref-type="fig"}), implicating that the SBE motif is critical for *SIRT7* transcriptional inhibition. Of note, TGF-β1 treatment significantly inhibited the expression of endogenous *SIRT7* (Figure [2H](#F2){ref-type="fig"}, below), wherein the SBE motif is intact. Together, the findings suggest that SMAD3/4 complex recognizes the *SIRT7* promoter to suppress transcription in response to TGF-β signaling.

HDAC8 is required for *SIRT7* transcriptional repression {#SEC3-3}
--------------------------------------------------------

Direct transcriptional repression by SMAD3/4 complex is rare ([@B20]). Instead, SMAD recruits deacetylase HDACs to repress transcription by chromatin remodeling ([@B19]). To test whether HDACs are involved in TGF-β-induced *SIRT7* transcriptional repression, we manipulated the enzyme activity of various HDACs by using Trichostatin A (TSA) and nicotinamide (NAM), which are specific class I/II and class III HDAC inhibitors respectively. TSA but not NAM treatment rescued TGF-β1-mediated transcriptional suppression of *SIRT7* (Figure [3A](#F3){ref-type="fig"}), suggesting the involvement of class I/II HDACs in the *SIRT7* transcriptional regulation. *PAI1* is transcriptionally regulated by HDACs ([@B13],[@B32]). We found increase of *PAI1* in response to NAM and TSA ([Supplementary Figure S3A](#sup1){ref-type="supplementary-material"}). Using selective HDAC inhibitors, we further narrowed down the candidates that likely suppress *SIRT7* transcription to HDAC6, 8, 10 and 11 ([Supplementary Figure S3B](#sup1){ref-type="supplementary-material"}, C and [Supplementary Table S1](#sup1){ref-type="supplementary-material"}). We then knocked down each of these candidates in MDA-MB-231 cells by siRNA ([Supplementary Figure S3D](#sup1){ref-type="supplementary-material"}). Only *HDAC8* KD restored *SIRT7* expression, which otherwise was suppressed by TGF-β1 (Figure [3B](#F3){ref-type="fig"}, C). Moreover, treatment with HDAC8 inhibitor PCI-34051 ([@B33]) restored SIRT7 levels in a dose-dependent manner (Figure [3D](#F3){ref-type="fig"}). On the other front, overexpression of ectopic *HDAC8* downregulated *SIRT7* expression and suppressed its promoter activity (Figure [3E](#F3){ref-type="fig"}--[G](#F3){ref-type="fig"}). Together, we reason that TGF-β signaling-mediated *SIRT7* repression is dependent on HDAC8.

![HDAC8 is required for *SIRT7* transcriptional repression. (**A**) qRT-PCR analysis of *SIRT7* in MDA-MB-231 cells treated with TGF-β1, NAM and TSA as indicated for 24 h. n.s, non-significant. The data represent the means ± s.e.m. *n* = 3, \**P* \< 0.05, \*\*\**P* \< 0.001; Student\'s *t*-test. (**B**, **C**) *SIRT7* levels were measured by qRT-PCR (B) and Immunoblotting (C) in *HDAC6*, *HDAC8*, *HDAC10* and *HDAC11* knocked down cells. The data represent the means ± s.e.m. *n* = 3, \*\**P* \< 0.01; Student\'s *t*-test. (**D**) Immunoblotting analysis of SIRT7 level in cells incubated with the HDAC8 inhibitor PCI-34051 (PCI), in the presence or absence of TGF-β1 (5 ng/ml). (**E**, **F**) Immunoblotting (E) and qRT-PCR analysis (F) of SIRT7 expression in cells with ectopic HDAC8 over-expression. The data represent the means ± s.e.m. *n* = 3, \*\*\**P* \< 0.001; Student\'s *t*-test. (**G**) Luciferase assay of *SIRT7* promoter activity with/without ectopic HDAC8 in the absence or presence of TGF-β1 (5 ng/ml). The data represent the means ± s.e.m.\**P* \< 0.05; Student\'s *t*-test.](gkaa039fig3){#F3}

HDAC8 induces repressive chromatin remodeling of *SIRT7* promoter {#SEC3-4}
-----------------------------------------------------------------

We hypothesized that SMAD3/4 might directly recruit HDAC8 to the *SIRT7* promoter. To address this, we did Co-IP and found that HDAC8 was immunoprecipitated with His-SMAD3 and HA-SMAD4 (Figure [4A](#F4){ref-type="fig"}, [B](#F4){ref-type="fig"}). Physical interaction of HDAC8-SMAD4 and HDAC8-SMAD3 was evidenced by immunoprecipitation of endogenous SMAD4 or SMAD3 (Figure [4C](#F4){ref-type="fig"}, [D](#F4){ref-type="fig"}). While *SMAD3* KD had little effect on the HDAC8--SMAD4 interaction, *SMAD4* KD markedly jeopardized the HDAC8--SMAD3 interaction (Figure [4E](#F4){ref-type="fig"}). On the other hand, forced expression of *SMAD4* significantly enhanced the SMAD3--HDAC8 interaction (Figure [4F](#F4){ref-type="fig"}). Furthermore, HDAC8 detectably interacted with SMAD4 but not SMAD3 based on pulldown assay in the test tube (Figure [4G](#F4){ref-type="fig"}). As determined by domain mapping, HDAC8 interacted with the MH2 domain of SMAD4, which is well dictated as an interface for binding transcriptional cofactors ([@B34]) ([Supplementary Figure S4A](#sup1){ref-type="supplementary-material"}). These data suggest that SMAD4 directly interacts with HDAC8 and acts as a linker in the SMAD3/4/HDAC8 complex.

![HDAC8 regulates chromatin remodeling of the SIRT7 promoter. (**A**) Immunoblotting analysis of HDAC8 and SMAD2/3 expression in anti-HA immunoprecipitates in HEK293 cells overexpressing ectopic HA-SMAD4. (**B**) Immunoblotting analysis of HDAC8 and SMAD4 levels in Ni-NAT-based pulldown from HEK293 cells overexpressing ectopic His-SMAD3. (**C**, **D**) IP of endogenous SMAD3 and SMAD4 in breast cancer MDA-MB-231 cells and immunoblotting analysis of HDAC8. (**E**) Immunoblotting analysis of SMAD2, SMAD3 and SMAD4 expression in anti-FLAG immunoprecipitates in HEK293 cells overexpressing FLAG-HDAC8 treated with indicated siRNAs. (**F**) Immunoblotting analysis of SMAD3 expression in anti-HDAC8 immunoprecipitates in HEK293 cells with or without ectopic SMAD4 overexpression. (**G**) *In vitro* Ni-NAT pulldown of purified His-SMAD3 and His-SMAD4 followed by immunoblotting of HDAC8. (**H**) Immunoblotting analysis of endogenous SMAD3 and SMAD4 expression in anti-HDAC8 immunoprecipitates in MDA-MB-231 breast cancer cells with indicated treatments. (**I**) Immunoblotting analysis of endogenous HDAC8 and SMAD3 expression in anti-SMAD4 immunoprecipitates with indicated treatments. (**J**) Immunoblotting analysis of nuclear HDAC8 in MDA-MB-231 breast cancer cells after TGF-β1 (5 ng/ml) treatment for indicated time. Histone H3 served as the loading control for nuclear proteins. (**K**, **L**) ChIP-qPCR analysis of HDAC8 enrichment on the *SIRT7* promoter region in MDA-MB-231 breast cancer cells (below). Immunoblotting analysis (upper) of SMAD protein expression. The data represent the means ± s.e.m. *n* = 3, \**P* \< 0.05, \*\*\**P* \< 0.001; Student\'s *t*-test. (**M**) ChIP-qPCR analysis of histone H4 acetylation levels at the *SIRT7* promoter under the indicated treatments (upper). Immunoblotting analysis (below) of HDAC8, p-SMAD3 and total histone H3 and H4 acetylation levels. The data represent the means ± s.e.m. n = 3, \*\**P* \< 0.01, \*\*\**P* \< 0.001; Student\'s *t*-test.](gkaa039fig4){#F4}

TGFβ induces SMAD3/4 oligomerization, which recruits cofactors to regulate gene transcription. Particularly, revealed by crystallographic data, SMADs oligomers were important for transcriptional complex stabilization ([@B35],[@B36]). We explored how TGFβ signaling regulates the SMAD3/4/HDAC8 complex formation. As shown, TGF-β1 treatment significantly enhanced the binding of HDAC8 to SMAD3/4, which was inhibited by *SMAD3* KD or *SMAD4* KD (Figure [4H](#F4){ref-type="fig"}, [I](#F4){ref-type="fig"}). By contrast, *HDAC8* KD hardly affected SMAD3/4 oligomerization. Consistent with the nuclear trans-localization of SMAD3/4 complex, TGF-β1 treatment also enhanced nuclear HDAC8 level (Figure [4J](#F4){ref-type="fig"}). Collectively, the data suggest that TGFβ signaling induces SMAD3/4 oligomerization, which in turn enhances HDAC8 recruitment and stabilizes the SMAD3/4/HDAC8 complex.

We next employed ChIP to assess whether HDAC8 is recruited to the SBE motif on *SIRT7* promoter. As shown, HDAC8 was markedly enriched on the SIRT7 promoter and TGF-β1 treatment significantly increased HDAC8 occupation, whereas *SMAD3* or *SMAD4* KD profoundly weakened it (Figure [4K](#F4){ref-type="fig"}, L). HDAC8 deacetylates histones H3 and H4 ([@B37],[@B38]). We used ChIP to examine histone H3 and H4 acetylation levels. As shown, decreased histone H4 but not H3 acetylation level on the *SIRT7* promoter was observed upon TGF-β1 treatment ([Supplementary Figure S4B](#sup1){ref-type="supplementary-material"}). We then knocked down *HDAC8* via siRNA and again performed ChIP based on H4 acetylation. Significantly, *HDAC8* KD restored H4 acetylation level (Figure [4M](#F4){ref-type="fig"}). Overall, these findings suggest that HDAC8 regulates local chromatin remodeling of the *SIRT7* promoter in response to TGF-β signaling by deacetylating H4.

HDAC8 hyperactivates TGF-β signaling via SIRT7-SMAD4 axis {#SEC3-5}
---------------------------------------------------------

SIRT7 promotes SMAD4 degradation and attenuates TGF-β signaling ([@B13]), we next examined whether HDAC8 is involved in SMAD4 regulation. We established CHX chase assay and found that *HDAC8* KD accelerated SMAD4 protein degradation in a SIRT7-dependent manner (Figure [5A](#F5){ref-type="fig"}), without affecting its mRNA ([Supplementary Figure S5A](#sup1){ref-type="supplementary-material"}). HDAC8 blockade by siRNA or PCI-34051 significantly inhibited TGF-β signaling, indicated by the expression of the downstream gene *PAI1*, *SLUG*, *CTGF* and *FN1* (Figure [5B](#F5){ref-type="fig"}, C). All together, we propose that SIRT7 deacetylates SMAD4, leading to its degradation and ensuring basal activity of TGF-β signaling ([@B13]) (Figure [5](#F5){ref-type="fig"}D(a)); HDAC8 cooperates with SMAD3/4 heterotrimer to suppress *SIRT7* transcription, causing hyperactivation of TGF-β signaling (Figure [5](#F5){ref-type="fig"}D(b)).

![HDAC8 inhibition attenuates TGF-β signaling. (**A**) SMAD4 protein levels in MDA-MB-231 breast cancer cells exposed to the indicated treatments. CHX, cycloheximide (50 μg/ml). (**B**, **C**) qRT-PCR analysis of TGF-β downstream genes in MDA-MB-231 breast cancer cells. The data represent the means ± s.e.m. *n* = 3, \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001; Student\'s *t*-test. (**D**) A schematic model: (a) SIRT7 deacetylates SMAD4, leading to its degradation and ensuring basal activity of TGF-β signaling; (b) HDAC8 cooperates with SMAD3/4 heterotrimer to suppress *SIRT7* transcription, causing hyperactivation of TGF-β signaling.](gkaa039fig5){#F5}

Targeting HDAC8 suppresses cancer metastasis and chemotherapy resistance {#SEC3-6}
------------------------------------------------------------------------

TGF-β signaling promotes breast cancer metastasis ([@B39],[@B40]). Inhibition of HDAC8 via PCI-34051 markedly attenuated breast cancer cell migration induced by TGF-β1; *SIRT7* KD completely abolished this effect (Figure [6A](#F6){ref-type="fig"} and [Supplementary Figure S5B](#sup1){ref-type="supplementary-material"}). We examined whether inhibiting *HDAC8* prevents breast cancer metastasis. We employed 4T1 murine breast cancer cells that can readily develop into lung metastases ([@B41]). As shown, PCI-34051 treatment (10 mg/Kg/mouse) markedly decreased lung metastatic nodules compared to the vehicle control, while simultaneous *SIRT7* KD largely attenuated the effect (Figure [6B](#F6){ref-type="fig"}. C and [Supplementary Figure S5C](#sup1){ref-type="supplementary-material"}). We noticed increased Sirt7 protein level in 4T1 tumors exposed to PCI-34051 (Figure [6C](#F6){ref-type="fig"}, below). By contrast, PCI-34051 treatment merely affected the acetylation levels of H3K18 and SMAD4, substrates of SIRT7, indicating that PCI-34051 less likely inhibits SIRT7 deacetylase activity ([Supplementary Figure S5E](#sup1){ref-type="supplementary-material"}. F). These findings implicate that HDAC8 inhibition suppresses breast cancer metastasis via SIRT7.

![HDAC8 inhibition suppresses cancer metastasis and attenuates chemotherapy resistance. (**A**) Transwell assay of MDA-MB-231 breast cancer cell migratory capacity after incubation with TGF-β1 or PCI-34051 (PCI), as indicated. Scale bar, 100 μm. (**B**) Representative H&E staining to detect lung metastasis of 4T1 breast cancer cells. Scram, mice inoculated with 4T1 cells treated with scrambled shRNA; Scram+PCI, mice inoculated with cells treated with scrambled shRNA and PCI-34051 (10 mg/kg body weight); KD7+PCI, mice inoculated with cells treated with *SIRT7* shRNA and PCI-34051. Scale bar, 0.5 mm. (**C**) Scatter plots (upper) of the number of lung metastatic nodules in individual mice in (B), *n* = 4 mice per group. IHC analysis of Sirt7 expression in lung metastasis sections (lower). \**P* \< 0.05; non-parametric Mann--Whitney *U*-test. Scale bar, 100 μm. (**D**) Immunoblotting analysis of SIRT7 levels in breast cancer cells treated with paclitaxel (PTX, 10 nM), PCI-34051 (PCI, 10 μM) or TβR1 inhibitor A83--01 (5 μM). (**E**) Crystal violet staining of control (shNC) and *SIRT7* knockdown (shSIRT7) cells with the indicated treatments. Scale bar, 200 μm. (**F**) CCK8 assay of TNBC BT549 and Hs578T cell viability under the indicated treatments. The data represent the means ± s.e.m. *n* = 3, \*\**P* \< 0.01, \*\*\**P* \< 0.001; Student\'s *t*-test. (**G**) Tumor volumes at the indicated time points in BALB/c mice treated with PTX (10 mg/kg), PCI (10 mg/kg) or PCI (10 mg/kg) + PTX (10 mg/kg). Mice were inoculated with 4T1 cells (5 × 10^5^) in the mammary fat pad 2 weeks before the treatment. \**P* \< 0.05 and \*\*\**P* \< 0.001; one-way ANOVA.](gkaa039fig6){#F6}

TGF-β signaling activation renders breast cancers insensitive to chemotherapy ([@B42]). SIRT7 is also downregulated by chemotherapeutic agents ([@B7]), and *SIRT7* KD induces chemoresistance to paclitaxel in breast cancer ([@B43]). We asked whether HDAC8 is involved in breast cancer chemoresistance via SIRT7-SMAD4 axis. Interestingly, the paclitaxel-induced downregulation of SIRT7 was rescued by A-8301 and PCI-34501 treatment in MDA-MB-231 cells (Figure [6D](#F6){ref-type="fig"} and [Supplementary Figure S5D](#sup1){ref-type="supplementary-material"}). It suggests that HDAC8 underlies SIRT7 reduction induced by paclitaxel. We asked whether blocking HDAC8 sensitizes breast cancer cells to paclitaxel. As shown, the combined treatment with paclitaxel and PCI-34051 eliminated cancer cells more effectively than just one treatment alone (Figure [6E](#F6){ref-type="fig"}, upper). *SIRT7* KD largely abrogated the effect of PCI-34051 (Figure [6E](#F6){ref-type="fig"}, lower). Likewise, TGF-β1-induced paclitaxel resistance was also attenuated by combined PCI-34051 treatment in BT549 and Hs578T breast cancer cells (Figure [6F](#F6){ref-type="fig"}). Importantly, PCI-34051 (10 mg/kg body weight) combined with paclitaxel (10 mg/kg body weight) greatly suppressed breast cancer growth in xenograft mouse model (Figure [6G](#F6){ref-type="fig"}). *SIRT7* KD reversed tumor growth inhibition induced by the combined treatment. Based on the survival analysis tool (<http://kmplot.com/>) ([@B44]), high *HDAC8* expression predicated poor prognosis in breast cancer patients ([Supplementary Figure S7](#sup1){ref-type="supplementary-material"}, left). Particularly, patients received chemotherapy with high *HDAC8* had much worse prognosis, further indicating a drug resistance role of HDAC8 ([Supplementary Figure S7](#sup1){ref-type="supplementary-material"}, right). These data suggest that HDAC8 blockade suppresses breast cancer lung metastasis and attenuates paclitaxel resistance.

DISCUSSION {#SEC4}
==========

We propose that TGF-β1 activates the SMAD3/4/HDAC8 complex, which translocate into the nucleus and suppresses *SIRT7* transcription via local H4 deacetylation. As a feedback, SIRT7 reduction activates TGF-β signaling and promotes related cellular functions, such as cell migration and cancer chemoresistance. HDAC8 inhibition represses TGF-β signaling, breast cancer metastasis and chemotherapy resistance.

SIRT7 has critical roles in ribosome biogenesis ([@B45],[@B46]), cellular stress responses ([@B4],[@B10],[@B47]), genome stability ([@B5],[@B48]), metabolic regulation ([@B11],[@B49]), aging ([@B8],[@B9]) and cancers ([@B50]). However, how SIRT7 is regulated at upstream is elusive. We have previously shown that SIRT7 deacetylates and destabilizes SMAD4, thus antagonizing TGF-β signaling ([@B13]). Here, we identified SIRT7 as a new target that is transcriptionally repressed by SMAD3/4 complex in collaboration with HDAC8, which mediates H4 deacetylation at local chromatin.

The association of SMADs with co-activators, such as CBP/p300, leads to chromatin remodeling via histone acetylation and modulates gene transcription ([@B19]). Conversely, transcriptional repression mediated by deacetylation may occur by recruiting HDACs to the SMAD binding sites ([@B20]). For example, SMAD3 recruits HDAC4/5 to mediate transcriptional repression of *Runx2* ([@B21]). Other than that, SMADs-mediated HDACs recruitment in suppressing transcription is rare. HDAC8 is the first human HDACs to be crystalized, however its roles are still obscure as few downstream target is found ([@B51]). We are first to show that HDAC8 is involved in TGF-β signaling, and SIRT7 is a *bona fide* transcriptional repression target of the SMAD3/4/HDAC8 complex. On the other front, acetylation/deacetylation of SMADs is also critical for TGFβ signaling. For instance, p300/CBP mediates SMAD3 acetylation and Sirt1/7 induces SMAD4 deacetylation ([@B13],[@B52],[@B53]). Albeit HDACs are frequently identified as SMAD-recruited components, they mainly regulate local chromatin remodeling rather than deacetylate SMADs ([@B34]). Herein, HDAC8 less likely deacetylates SMAD3 or SMAD4 (see [Supplementary Figure S6A, B](#sup1){ref-type="supplementary-material"}). Previous studies suggest that HDAC8 could be a potential therapeutic target as it enhances breast cancer stemness and invasion. This is consistent with its effect on *SIRT7* repression, as SIRT7 inhibits breast cancer stemness and metastasis ([@B13],[@B54]). HDAC3 is the closest HDAC8 human homolog ([@B55]). Interestingly, HDAC3 represses SIRT7 expression in hepatocellular carcinoma via C/EBPα ([@B56]). However, such a suppressive effect was merely observed in TGF-β signaling. The diversified effects suggest that the regulation of SIRT7 might be determined by specific physiological context. Phenotypical studies suggest SIRT7 as an aging-related gene and its level is significantly decreased during aging ([@B9],[@B10]). As such, it would be interesting to explore whether HDAC8 is involved in age-related diseases, such as tissue fibrosis and cardiovascular dysfunction.

The role of SIRT7 in cancers is hotly debated. SIRT7 is aberrantly increased in CRC, HCC, early stage breast cancers and thyroid cancers ([@B57]). Many studies have shown that SIRT7 promotes tumor cell growth, emphasizing an oncogenic action. Seemingly contradictory, SIRT7 inhibits metastasis in breast cancers and oral squamous cell carcinomas by antagonizing TGF-β signaling ([@B13],[@B58]). Our finding that SIRT7 is downregulated by TGF-β provides a reasonable explanation for this effect; furthermore, it is well known that TGF-β is a 'double-edged sword' in the cancer context ([@B59]). During the pre-malignant stage, TGF-β has a tumor suppressive role by inducing cell-cycle arrest and apoptosis ([@B59]). Malignant cancers often bypass this unfavorable effect, e.g. mutations in TβR`II`, SMAD2 and SMAD4 are common in HCC, CRC, pancreatic cancer and lung cancer ([@B39]), which obtain a growth advantage, consistent with the oncogenic role of SIRT7. Conversely, for breast cancers, TGF-β signaling is intact, and is instead engaged to promote cancer-cell EMT, stemness and metastasis. SIRT7 promotes SMAD4 degradation and antagonizes TGF-β signaling ([@B13]). Our finding that TGF-β transcriptionally represses *SIRT7* partially explains low SIRT7 expression in breast cancer lung metastases. As an attractive target for drug development, due to the aforementioned complicated roles, however, it is critical to consider the functional diversities of SIRT7 and select patients who could obtain the best benefit.

TNBCs are the most malignant breast cancer subtype, and are characterized by high metastasis and poor prognosis ([@B60]). To date, TNBCs still lack well-defined molecular targets: traditional chemotherapy (such as paclitaxel) and surgery are most widely applied ([@B61]). While initial paclitaxel treatment is effective for some patients, many patients later develop resistance ([@B62]) that is largely attributed to TGF-β activation ([@B42]). We found that HDAC8 enhances cell migration and boosts cancer stemness in TNBCs and PCI-34051 abrogates breast cancer lung metastasis and TGF-β-induced paclitaxel resistance by repressing SIRT7, suggesting that HDAC8 or its targets has therapeutic potential ([@B24],[@B63],[@B64]).
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